In a forthcoming paper, the Review on Antimicrobial Resistance estimates that bringing new antimicrobials to market and improving their administration will cost about $25 billion – a significant sum, but one that pales in comparison to the costs to society if the problem is not checked. It is also roughly what two of the world’s largest pharmaceutical companies will spend this year buying back their own shares.
实现这一点的一个重要途径是开发新药。在一篇即将发表的文章中，抗耐药性评估（Review on Antimicrobial Resistance）估计，实现新抗生素上市并改善它们的管理需要耗资大约250亿美元——一笔巨款，但和问题得不到解决所引起的社会成本相比只是九牛一毛。而这也是世界最大的两家制药公司今年用于回购本公司股票的金额。